Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Contempt charge “they” want you to know about

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission alleges author and infomercial personality Kevin Trudeau violated a court order issued as part of a 2004 settlement by making false representations about the weight-loss plan outlined in his book "The Weight Loss Cure 'They' Don't Want You to Know About." The 2004 order, which settled charges of false claims related to coral calcium and other products, banned Trudeau from using infomercials to sell any product service or program (1"The Tan Sheet" Sept. 13, 2004, In Brief). However, it allowed a narrow exemption for promoting books, provided he "not misrepresent the content of the books," FTC notes. In an infomercial, Trudeau called the book's weight-loss regimen "easy," and said when it is completed one can "eat whatever you want and you don't gain the weight back," the commission says. According to FTC, consumers buying the book "find it actually describes a complicated, expensive system involving daily injections, specialized cleanses and supplements, and severe food restrictions, followed by a 'fourth phase' of the protocol, which requires dietary restrictions and never ends." FTC's Sept. 13 brief filed in the U.S. District Court for the Northern District of Illinois asks for Trudeau to be found in contempt and ordered to pay consumer redress...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel